zanubrutinib

targets

all catalysts(1)

News(6)

• Mid-cap biotechs join Trump’s latest round of drug pricing deals
  Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
  biopharma_dive · 1mo ago
• BeOne commits $300M to US manufacturing expansion, creating 120 new jobs
  The addition of small molecule capacity at BeOne Medicines’ Hopewell site will support the company’s hematology efforts and bring total investment in the campus to more than $1 billion.
  biospace · 2mo ago
• Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
  The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
  biopharma_dive · 3mo ago
• BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma study
  BeOne Medicines said its BTK inhibitor Brukinsa cut the risk of disease progression or death by 43% compared to chemoimmunotherapy when used as a first option for mantle cell lymphoma patients. The…
  endpoints · 3mo ago
• Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
  Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted i…
  biopharma_dive · 4mo ago
• Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL
  Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.
  onclive · 5mo ago